Research graph
References from Promising new approaches. Local targets link to admitted publications; unresolved targets remain external evidence.
Thiazolidinediones in the treatment of insulin resistance and type II diabetes.
10.2337/diab.45.12.1661 · 1996 · External reference
Sibutramine in the treatment of overweight non‐insulin‐dependent diabetics.
1995 · External reference
Sibutramine – a review of clinical efficacy.
1997 · External reference
Selective beta 3‐adrenergic agonist of brown adipose tissue and thermogenesis.
1992 · External reference
10.1055/s-2007-979932
10.1055/s-2007-979932 · External reference
Rosiglitazone improves insulin sensitivity and reduces hyperexpression of insulin and amylin mRNA’s in pancreatic islets.
1998 · External reference
10.1046/j.1463-1326.1999.0010s1008.x · Admitted local publication
10.1210/en.137.10.4189
10.1210/en.137.10.4189 · External reference
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator‐activated receptor γ (PPARγ).
10.1074/jbc.270.22.12953 · 1995 · External reference
10.1016/0021-9150(96)05811-x
10.1016/0021-9150(96)05811-x · External reference
10.1016/0006-2952(95)00235-r
10.1016/0006-2952(95)00235-r · External reference
10.2337/diacare.18.5.666
10.2337/diacare.18.5.666 · External reference
10.1056/nejm199803263381314
10.1056/nejm199803263381314 · External reference
10.7326/0003-4819-129-1-199807010-00009
10.7326/0003-4819-129-1-199807010-00009 · External reference
Effects of troglitazone monotherapy in patients with NIDDM. a 6‐month multicenter study.
1997 · External reference
Unresolved reference
External reference
The Rosiglitazone Study Group. Rosiglitazone (BRL49653) monotherapy has significant glucose lowering effect in type 2 diabetic patients.
1998 · External reference
Cytochrome P450: new nomenclature and clinical implications.
1998 · External reference
10.1097/00007890-199805270-00021
10.1097/00007890-199805270-00021 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.2337/diacare.21.9.1462
10.2337/diacare.21.9.1462 · External reference
10.2337/diacare.18.6.775
10.2337/diacare.18.6.775 · External reference
10.1056/nejm199803263381303
10.1056/nejm199803263381303 · External reference
Effect of troglitazone in insulin‐treated patients with type II diabetes mellitus.
1998 · External reference
Unresolved reference
1996 · External reference
10.2337/diabetes.47.8.1326
10.2337/diabetes.47.8.1326 · External reference
Effect of troglitazone on body fat distribution in NIDDM patients.
1998 · External reference
10.4158/ep.4.3.146
10.4158/ep.4.3.146 · External reference
10.1007/bf00400196
10.1007/bf00400196 · External reference
10.1210/jcem-61-5-917
10.1210/jcem-61-5-917 · External reference
10.2337/diacare.21.1.s32
10.2337/diacare.21.1.s32 · External reference
Metabolic consequences of very‐low‐calorie diet therapy in obese non‐insulin‐dependent diabetic and nondiabetic subjects.
10.2337/diab.35.2.155 · 1986 · External reference
Obesity. an escalating problem.
1997 · External reference
Unresolved reference
External reference
